Expertise in
2
conditions

Dr. Geoffrey S. Gladstein

Rheumatology
Office
5520 Park Ave Ste 101, 
Trumbull, CT 
Accepting New Patients
Referral may be required
Before you request
Expertise in
2
conditions
Office
5520 Park Ave Ste 101, 
Trumbull, CT 

Overview

Geoffrey Gladstein is a Rheumatologist practicing medicine in Trumbull, Connecticut.

Dr. Gladstein is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Arthritis, and Axial Spondyloarthritis (AxSpA).

He is actively involved in clinical research, participating in 11 clinical trials. Dr. Gladstein is currently accepting new patients.

Specialties

Rheumatology

Licenses

Specialist in CT

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
5520 Park Ave Ste 101, Trumbull, CT 06611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (51.8 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist practicing medicine in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required
Before you request

Hospital For Special Surgery-Main Hospital

535 E 70th St Fl 6, 
New York, NY 
 (51.9 miles away)
212-606-1163
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Goodman is a Rheumatologist practicing medicine in New York, New York. Dr. Goodman is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, Knee Replacement, and Hip Replacement. Dr. Goodman is currently accepting new patients.

Expertise in
6
conditions
Expertise in
6
conditions
Referral may be required
Before you request

North Haven Medical Center-Radiology

6 Devine St, 
North Haven, CT 
 (19.1 miles away)
203-287-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Monique Hinchcliff is a Rheumatologist practicing medicine in North Haven, Connecticut. Dr. Hinchcliff is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Raynaud Phenomenon, Scleroma, and Tissue Biopsy. Dr. Hinchcliff is currently accepting new patients.

Frequently Asked Questions about Dr. Geoffrey S. Gladstein

How do I make an appointment with Dr. Geoffrey S. Gladstein?

You can book an appointment with Dr. Geoffrey S. Gladstein by calling their office at 203-371-5873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Geoffrey S. Gladstein a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Geoffrey S. Gladstein is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Geoffrey S. Gladstein specialize in?

While Dr. Geoffrey S. Gladstein is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Geoffrey S. Gladstein accept my insurance?

Dr. Geoffrey S. Gladstein accepts most major insurance plans, including Humana. We recommend calling the office directly at 203-371-5873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gladstein's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile